Public-plan records, documented services and the questions the available sources cannot settle.
What this page answers
Semaglutide for diabetes on the public plan: Médicament d'exception (diabetes) for Ozempic, Rybelsus and the four generic DINs.
Weight-management products on the public plan: Wegovy, Saxenda, Zepbound and Sevmia returned no result in the RAMQ covered-drug search on 2026-09-17.
Services documented as offered in Quebec: 1 of 7 checked, on the companies' own pages.
Public care route: not researched for this record.
Evidence depth: moderateDepth describes the research scope, not coverage and not clinical quality.
Public coverage record
Evidence depth: moderateModerate: generic listings and diabetes criteria were read from opened documents; some fields (for example interchangeability) are unknown.
Public plan record for Quebec, as read from the documents named below
Semaglutide for type 2 diabetes (public plan)
Médicament d'exception (diabetes) for Ozempic, Rybelsus and the four generic DINs; criterion: T2D with metformin where sulfonylurea is contraindicated, not tolerated or ineffective; injected reimbursement ceiling 1 mg weekly
Weight-management products (public plan)
Wegovy, Saxenda, Zepbound and Sevmia returned no result in the RAMQ covered-drug search on 2026-09-17. Earlier pass noted an April 2026 RAMQ decision declining Wegovy and an INESSS pilot recommendation; confirm in R3-1
Imcivree for rare genetic obesity
Imcivree not found in RAMQ search
Generic interchangeability with Ozempic
unknown: legal list has separate semaglutide and semaglutide (generic) headings; cross-brand interchangeability not established. R3-1 to close
Source document date
Liste des médicaments effective 2026-08-27; live search 2026-09-17
Public care route observed
not researched; French clinical service availability not verified
A listing is not a decision about an individual claim. Criteria, special authorization and the plan's own process still apply.
Services that mention Quebec
Seven services were checked. Each record is what the company's own pages said on the access date.
Documented matches, in alphabetical order
The company's own page names this jurisdiction for its weight service on the access date. Company self-report is not a licence check and not a quality signal.
Weight page FAQ says all Canadian provinces. Territories not named. Wording is a blanket statement, not a province-by-province list; keep the label company self-report. R22-C91R41-C51R41-C52
Recorded state, as written in the data
company self-report: offered
Operator
Hims & Hers Canada Inc.
Initial care fee, as displayed
Free in English and French browser views; $99 still in extracted text of both
Recurring care fee, as displayed
Weight-specific fee unknown
Source undated (live page and text extraction differed on consult fee)Accessed 2026-09-23
These records are conflicting, not found in the sources checked, explicitly not offered, not applicable or not researched. They are never mixed in with matches.
Doctor/NP assessment, ongoing reviews and renewals
Conflicting
Three Maple pages disagree. Help page (17 Apr 2026): all locations except NS, NU, NT. Assessment landing page: AB, BC, MB, NB, NL, ON, PEI, QC, SK, Yukon. Obesity page: complimentary assessment in Ontario only. Only ON appears on all three. Display as a dated conflict. R22-C32R22-C33A-C34R41-C19R41-C20R41-C21
Recorded state, as written in the data
conflicting (help page and assessment page name it; obesity page says Ontario only)
Operator
Maple Corporation
Initial care fee, as displayed
Covered by membership (help page); Ontario only per obesity page (conflicting)
Recurring care fee, as displayed
General membership $85/month outside QC; $95/month QC
Referral to specialist; groups and continuing physician support
Not applicable
MSP-covered program for BC residents, virtual or clinic visits, physician referral required. No other province named on checked pages; a BC MSP program is not applicable outside BC. R22-C71R22-C72B-C14aR41-C68
Recorded state, as written in the data
not applicable (BC MSP program)
Operator
Legal operator not found; OMDI/Medical Weight Management branding
Weight service list is six provinces. The general platform list adds NS and NL for other categories only; treat NS and NL as explicitly not offered for weight. Territories and QC, NB not named on either list. R22-C02R22-C04R41-C01R41-C02
Recorded state, as written in the data
not found in sources checked
Operator
Felix Inc.; Felix Health Inc. also appears
Initial care fee, as displayed
Main free; funnel $99
Recurring care fee, as displayed
$40 follow-up
Source 2026-09-16 (page said updated yesterday on 2026-09-17)Accessed 2026-09-23
No weight-service province or territory list found on the three checked pages. Partner pharmacy is an Ontario corporation (ScaleRx), which does not establish prescribing reach. R22-C98R22-C102R41-C75R41-C76R41-C77
Recorded state, as written in the data
not found in sources checked
Operator
Jack and Jill Health Inc.
Initial care fee, as displayed
$0 initial fee (waived), then $59/month; not a free first month
No weight-specific province list found. Platform terms exclude Quebec and describe pharmacy delivery to provinces and territories; delivery reach is not prescribing reach. Pharmacy operators are in BC and ON. R22-C105R22-C106R22-C111R41-C86R41-C87R41-C88
Recorded state, as written in the data
explicitly not offered (platform terms exclude Quebec)
not researched; French clinical service availability not verified
Quebec. The RAMQ terms above are French, with English glosses marked as translations in the research. A French version of this site does not exist yet and will not until a review process for French content exists. The research also flagged Law 25 and Charter of the French language questions for a Quebec audience.
What this page cannot say yet
Next research step recorded for this jurisdiction: R3-1 Part 1. Recheck assumption: every 30 days for coverage and every 7 days for service pages.
Company self-report: offeredThe company's own page says it offers the service there. This is not a check of licensing or quality.
ConflictingTwo or more of the company's own pages disagree. Both values are shown with their dates.
Not found in sources checkedThe researcher looked and did not find it. This is not the same as not offered.
Explicitly not offeredThe company's page says it does not serve that place.
Not applicableThe service is a public program limited to one province by design.
Not researchedNobody has looked yet.
Sources for this page
Every claim ID below is a row in the evidence ledger. The source date is the date the source itself carries; the access date is when the researcher opened it. A claim with several rows is one claim with several sources, not several confirmations.
This table scrolls sideways.
Source records for every claim cited on this page
Claim
What the source says
Source
Source date
Accessed
Label
A-C25
RAMQ lists semaglutide brands/generics as exception medications
date not shown; current legal list effective 2026-08-27
2026-09-17
regulator-confirmed
R21-C547
RAMQ legal list effective August27 2026 has separate semaglutide and semaglutide(generic) headings; generic DINs02567806,02568012,02567814,02568020 are listed. Cross-brand Ozempic interchangeability not established from these headings.
RAMQ semaglutide exception criterion treats T2DM with metformin where sulfonylurea is contraindicated, not tolerated or ineffective; injected reimbursement ceiling1mg weekly and oral14mg daily.
A weight-management benefit was not established from the RAMQ semaglutide search and legal-list sections checked; searches for Imcivree/setmelanotide did not produce an extracted match.
